

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

NCT06192979

Status	RECRUITING
Phase	Not Applicable
Sponsor	Jin Lu, MD
Enrollment	41 participants

Key Eligibility Criteria

Inclusion (7)

- Diagnosis of systemic AL amyloidosis;
- Daratumumab, bortezomib, dexamethasone used in 1st line treatment;
- Life expectancy greater than 12 weeks;
- HGB ≥ 70 g/L;
- Blood oxygen saturation $\geq 90\%$;
- ... and 2 more (see full listing online)

Exclusion (7)

- Fulfill with the criteria of active multiple myeloma or active lymphoplasmacytic lymphoma.
- Presence of other tumors which is/are in advanced malignant stage and has/have systemic metastasis;
- Severe or persistent infection that cannot be effectively controlled;
- Presence of severe autoimmune diseases or immunodeficiency disease;
- Patients with active hepatitis B or hepatitis C (\backslash [HBVDNA+] or \backslash [HCVRNA+]);
- ... and 2 more (see full listing online)

Locations (6 total)

Peking University People's Hospital, Beijing, Beijing Municipality, China
Capital Medical University Affiliated Fuxing Hospital, Beijing, Beijing Municipality, China
Beijing Anzhen Hospital, Beijing, Beijing Municipality, China
... and 3 more locations